Keith Katkin, President and CEO at AVANIR PHARMACEUTICALS, INC. (AVNR), sold 442,212 shares at $5.01 ($2.2M) on 2014-05-28, disclosed to the SEC on 2014-05-30.
Scheduled sale ($2.2M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| SNDX | BUY | 2025-05-19 | $91K | — | Filing → |
| SNDX | SELL | 2022-10-07 | $1.5M | — | Filing → |
| SNDX | SELL | 2022-10-04 | $176K | — | Filing → |